Mining and analysis of adverse event signals of trastuzumab deruxtecan via real-world data of FDA adverse event reporting system database from 2019 to 2023

Background Trastuzumab deruxtecan (T-DXd) is a novel generation antibody-drug conjugate. However, current evidence for the safety of T-DXd is mostly limited to clinical trials. It resulted in inability to timely update the adverse event (AE) for drug. Therefore, we mine and analyze AE signals caused by T-DXd based on the FAERS database, and to provide reference for the safe use of drug in clinical practice and reduce the occurrence of AE.